Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4445372 | 1.00 | EPHX2 (1.00) | EPHX2ALOX5 | |
| SCHEMBL14424455 | 0.94 | EPHX2 (0.88) | EPHX2 | |
| SCHEMBL12931855 | 0.90 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL12931853 | 0.89 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL2050549 | 0.89 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL2325195 | 0.88 | EPHX2 (0.97) | EPHX2 | |
| SCHEMBL14503292 | 0.87 | EPHX2 (0.77) | EPHX2 | |
| SCHEMBL12931834 | 0.86 | EPHX2 (0.82) | EPHX2ALOX5 | |
| SCHEMBL12931851 | 0.86 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL12932025 | 0.86 | EPHX2 (0.88) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | disclosed |
| US-12357598-B2 | Treatment of neurodevelopmental disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-15 | — | — | US | disclosed |
| US-12251379-B2 | Methods of inhibiting formation of alpha synuclein aggregates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-18 | — | — | US | disclosed |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | CHIBA UNIVERSITY (JP) | 2023-09-28 | — | — | US | disclosed |
| US-11723929-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | disclosed |
| US-11690837-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230071934-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2023-03-09 | — | — | US | disclosed |
| US-11564914-B2 | Methods of treating bone loss | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-31 | — | — | US | disclosed |
| US-11426385-B2 | Methods of improving cancer chemotherapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220202744-A1 | METHODS OF TREATING MENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-30 | — | — | US | disclosed |
| EP-1608319-A2 | IMPROVED INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | The Regents of the University of California (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2005094373-A2 | CIS-EPOXYEICOSANTRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND METHODS TO REDUCE PULMONARY INFILTRATION BY NEUTROPHILS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050222252-A1 | Use of cis-Epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-10-06 | — | — | US | disclosed |
| WO-2005089380-A2 | REDUCING NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND EPOXYEICOSANOIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-29 | — | — | WO | disclosed |
| EP-1575489-A2 | USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO INHIBIT VASCULAR SMOOTH MUSCLE CELL PROLIFERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050164951-A1 | Inhibitors for the soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-07-28 | — | — | US | disclosed |
| US-20050026844-A1 | Inhibitors for the soluble epoxide hydrolase | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | US | disclosed |
| WO-2004089296-A2 | IMPROVED INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2003061597-A2 | USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO INHIBIT VASCULAR SMOOTH MUSCLE CELL PROLIFERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-07-31 | — | — | WO | disclosed |
| US-20030139469-A1 | Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | FABP7, ADH1B, ELOVL1 | EPHX2 51/4885ALOX5 24/4885 |
| US-11723929-B2 | Methods of improving cell-based therapy | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885ALOX5 81/4885 |
| US-20220202744-A1 | METHODS OF TREATING MENTAL DISORDERS | FAAH, EPHX1, FAAH2 | EPHX2 4/4885ALOX5 22/4885 |
| US-12357598-B2 | Treatment of neurodevelopmental disorders | FABP7, ADH1B, ELOVL1 | EPHX2 51/4885ALOX5 24/4885 |
| US-20050164951-A1 | Inhibitors for the soluble epoxide hydrolase | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885ALOX5 58/4885 |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | EED, ICOS, FABP7 | EPHX2 10/4885ALOX5 23/4885 |
| US-12251379-B2 | Methods of inhibiting formation of alpha synuclein aggregates | SNCA, PARK7, PYGB | EPHX2 3967/4885ALOX5 2433/4885 |
| US-11690837-B2 | Methods of improving cell-based therapy | ELOVL1, ELOVL3, IL2 | EPHX2 127/4885ALOX5 37/4885 |
| US-11564914-B2 | Methods of treating bone loss | EPHX1, NCEH1, SOST | EPHX2 4/4885ALOX5 59/4885 |
| US-20230071934-A1 | NOVEL USES | SMPD1, PDE4A, PDE7A | EPHX2 534/4885ALOX5 94/4885 |
| US-20050026844-A1 | Inhibitors for the soluble epoxide hydrolase | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885ALOX5 58/4885 |
| US-11426385-B2 | Methods of improving cancer chemotherapy | ALOX5, EPHX1, ALOX12 | EPHX2 10/4885ALOX5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.